title: Integrating phosphoproteomics into the clinical management of prostate cancer.
abstract: Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to soon translate this information into the cancer clinic.
authors.affiliation: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA.|Graduate Program in Cellular and Molecular Pharmacology, Graduate School of Biomedical Sciences, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.|Graduate Program in Quantitative Biomedicine, Graduate School-New Brunswick, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
authors.forename: Larry C
authors.initials: LC
authors.lastname: Cheng
authors.affiliation: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA.|Graduate Program in Cellular and Molecular Pharmacology, Graduate School of Biomedical Sciences, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.|Graduate Program in Quantitative Biomedicine, Graduate School-New Brunswick, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
authors.forename: Victor M
authors.initials: VM
authors.lastname: Tan
authors.affiliation: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA.|Division of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08901, USA.
authors.forename: Shridar
authors.initials: S
authors.lastname: Ganesan
authors.affiliation: Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA. justin.drake@cinj.rutgers.edu.|Graduate Program in Cellular and Molecular Pharmacology, Graduate School of Biomedical Sciences, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA. justin.drake@cinj.rutgers.edu.|Graduate Program in Quantitative Biomedicine, Graduate School-New Brunswick, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA. justin.drake@cinj.rutgers.edu.|Division of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08901, USA. justin.drake@cinj.rutgers.edu.
authors.forename: Justin M
authors.initials: JM
authors.lastname: Drake
keywords: Biomarkers; Clinical diagnostics; Clinical trial design; Kinase inhibitors; Mass spectrometry; Pharmacotherapy; Phosphoproteomics; Precision medicine; Prostate cancer